Europe Antidiabetic Thiazolidinediones Market Report 2018

Table of Contents

1 Report Overview

• 1.1 Definition and Specification
• 1.2 Report Overview
  • 1.2.1 Manufacturers Overview
  • 1.2.2 Regions Overview
  • 1.2.3 Type Overview
  • 1.2.4 Application Overview
• 1.3 Industrial Chain
  • 1.3.1 Antidiabetic Thiazolidinediones Overall Industrial Chain
  • 1.3.2 Upstream
  • 1.3.3 Downstream
• 1.4 Industry Situation
  • 1.4.1 Industrial Policy
  • 1.4.2 Product Preference
  • 1.4.3 Economic/Political Environment
• 1.5 SWOT Analysis

2 Market Analysis by Types

• 2.1 Overall Market Performance(Volume)
  • 2.1.1 Rosiglitazone Market Performance (Volume)
  • 2.1.2 Pioglitazone Market Performance (Volume)
• 2.2 Overall Market Performance(Value)
  • 2.1.1 Rosiglitazone Market Performance (Value)
  • 2.1.2 Pioglitazone Market Performance (Value)

3 Product Application Market

• 3.1 Overall Market Performance (Volume)
  • 3.1.1 Hospitals Market Performance (Volume)
  • 3.1.2 Clinics Market Performance (Volume)
  • 3.1.3 Other Market Performance (Volume)

4 Manufacturers Profiles/Analysis

• 4.1 Sanofi
  • 4.1.1 Sanofi Profiles
  • 4.1.2 Sanofi Product Information
  • 4.1.3 Sanofi Antidiabetic Thiazolidinediones Business Performance
  • 4.1.4 Sanofi Antidiabetic Thiazolidinediones Business Development and Market Status
• 4.2 Takeda Pharmaceuticals
  • 4.2.1 Takeda Pharmaceuticals Profiles
  • 4.2.2 Takeda Pharmaceuticals Product Information
  • 4.2.3 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Business Performance
  • 4.2.4 Takeda Pharmaceuticals Antidiabetic Thiazolidinediones Business Development and Market Status
• 4.3 Eli Lilly
  • 4.3.1 Eli Lilly Profiles
  • 4.3.2 Eli Lilly Product Information
  • 4.3.3 Eli Lilly Antidiabetic Thiazolidinediones Business Performance
  • 4.3.4 Eli Lilly Antidiabetic Thiazolidinediones Business Development and Market Status
• 4.4 Merck & Co.
  • 4.4.1 Merck & Co. Profiles
  • 4.4.2 Merck & Co. Product Information
  • 4.4.3 Merck & Co. Antidiabetic Thiazolidinediones Business Performance
  • 4.4.4 Merck & Co. Antidiabetic Thiazolidinediones Business Development and Market Status
• 4.5 Novo Nordisk
  • 4.5.1 Novo Nordisk Profiles
  • 4.5.2 Novo Nordisk Product Information
  • 4.5.3 Novo Nordisk Antidiabetic Thiazolidinediones Business Performance
  • 4.5.4 Novo Nordisk Antidiabetic Thiazolidinediones Business Development and Market Status
• 4.6 Bristol-Myers Squibb
  • 4.6.1 Bristol-Myers Squibb Profiles
  • 4.6.2 Bristol-Myers Squibb Product Information
  • 4.6.3 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Business Performance
  • 4.6.4 Bristol-Myers Squibb Antidiabetic Thiazolidinediones Business Development and Market Status
• 4.7 Pfizer
  • 4.7.1 Pfizer Profiles
  • 4.7.2 Pfizer Product Information
  • 4.7.3 Pfizer Antidiabetic Thiazolidinediones Business Performance
  • 4.7.4 Pfizer Antidiabetic Thiazolidinediones Business Development and Market Status
• 4.8 AstraZeneca
  • 4.8.1 AstraZeneca Profiles
  • 4.8.2 AstraZeneca Product Information
  • 4.8.3 AstraZeneca Antidiabetic Thiazolidinediones Business Performance
  • 4.8.4 AstraZeneca Antidiabetic Thiazolidinediones Business Development and Market Status
• 4.9 GlaxoSmithKline
  • 4.9.1 GlaxoSmithKline Profiles
  • 4.9.2 GlaxoSmithKline Product Information
  • 4.9.3 GlaxoSmithKline Antidiabetic Thiazolidinediones Business Performance
  • 4.9.4 GlaxoSmithKline Antidiabetic Thiazolidinediones Business Development and Market Status
• 4.10 Boehringer Ingelheim
  • 4.10.1 Boehringer Ingelheim Profiles
  • 4.10.2 Boehringer Ingelheim Product Information
  • 4.10.3 Boehringer Ingelheim Antidiabetic Thiazolidinediones Business Performance
  • 4.10.4 Boehringer Ingelheim Antidiabetic Thiazolidinediones Business Development and Market Status

5 Market Performance for Manufacturers

• 5.1 Europe Antidiabetic Thiazolidinediones Sales (K Units) and Market Share by Manufacturers 2013-2018
• 5.2 Europe Antidiabetic Thiazolidinediones Revenue (M USD) and Market Share by Manufacturers 2013-2018
• 5.3 Europe Antidiabetic Thiazolidinediones Price (USD/Unit) of Manufacturers 2013-2018
• 5.4 Europe Antidiabetic Thiazolidinediones Gross Margin of Manufacturers 2013-2018
• 5.5 Market Concentration

6 Regions Market Performance for Manufacturers

• 6.1 Germany Market Performance for Manufacturers
  • 6.1.1 Germany Antidiabetic Thiazolidinediones Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.1.2 Germany Antidiabetic Thiazolidinediones Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.1.3 Germany Antidiabetic Thiazolidinediones Price (USD/Unit) of Manufacturers 2013-2018
  • 6.1.4 Germany Antidiabetic Thiazolidinediones Gross Margin of Manufacturers 2013-2018
  • 6.1.5 Market Concentration
• 6.2 UK Market Performance for Manufacturers
  • 6.2.1 UK Antidiabetic Thiazolidinediones Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.2.2 UK Antidiabetic Thiazolidinediones Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.2.3 UK Antidiabetic Thiazolidinediones Price (USD/Unit) of Manufacturers 2013-2018
  • 6.2.4 UK Antidiabetic Thiazolidinediones Gross Margin of Manufacturers 2013-2018
  • 6.2.5 Market Concentration
• 6.3 France Market Performance for Manufacturers
  • 6.3.1 France Antidiabetic Thiazolidinediones Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.3.2 France Antidiabetic Thiazolidinediones Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.3.3 France Antidiabetic Thiazolidinediones Price (USD/Unit) of Manufacturers 2013-2018
  • 6.3.4 France Antidiabetic Thiazolidinediones Gross Margin of Manufacturers 2013-2018
  • 6.3.5 Market Concentration
• 6.4 Russia Market Performance for Manufacturers
  • 6.4.1 Russia Antidiabetic Thiazolidinediones Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.4.2 Russia Antidiabetic Thiazolidinediones Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.4.3 Russia Antidiabetic Thiazolidinediones Price (USD/Unit) of Manufacturers 2013-2018
  • 6.4.4 Russia Antidiabetic Thiazolidinediones Gross Margin of Manufacturers 2013-2018
  • 6.4.5 Market Concentration
• 6.5 Benelux Market Performance for Manufacturers
  • 6.5.1 Benelux Antidiabetic Thiazolidinediones Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.5.2 Benelux Antidiabetic Thiazolidinediones Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.5.3 Benelux Antidiabetic Thiazolidinediones Price (USD/Unit) of Manufacturers 2013-2018
  • 6.5.4 Benelux Antidiabetic Thiazolidinediones Gross Margin of Manufacturers 2013-2018
  • 6.5.5 Market Concentration
• 6.6 Italy Market Performance for Manufacturers
  • 6.6.1 Italy Antidiabetic Thiazolidinediones Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.6.2 Italy Antidiabetic Thiazolidinediones Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.6.3 Italy Antidiabetic Thiazolidinediones Price (USD/Unit) of Manufacturers 2013-2018
  • 6.6.4 Italy Antidiabetic Thiazolidinediones Gross Margin of Manufacturers 2013-2018
  • 6.6.5 Market Concentration
• 6.7 Spain Market Performance for Manufacturers
  • 6.7.1 Spain Antidiabetic Thiazolidinediones Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.7.2 Spain Antidiabetic Thiazolidinediones Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.7.3 Spain Antidiabetic Thiazolidinediones Price (USD/Unit) of Manufacturers 2013-2018
  • 6.7.4 Spain Antidiabetic Thiazolidinediones Gross Margin of Manufacturers 2013-2018
  • 6.7.5 Market Concentration
• 6.8 Market Performance for Manufacturers
  • 6.8.1 Antidiabetic Thiazolidinediones Sales (K Units) and Share of Manufacturers 2013-2018
  • 6.8.2 Antidiabetic Thiazolidinediones Revenue (M USD) and Share of Manufacturers 2013-2018
  • 6.8.3 Antidiabetic Thiazolidinediones Price (USD/Unit) of Manufacturers 2013-2018
  • 6.8.4 Antidiabetic Thiazolidinediones Gross Margin of Manufacturers 2013-2018
  • 6.8.5 Market Concentration

7 Europe Antidiabetic Thiazolidinediones Market Performance (Sales Point)

• 7.1 Europe Antidiabetic Thiazolidinediones Sales (K Units) and Market Share by Regions 2013-2018
• 7.2 Europe Antidiabetic Thiazolidinediones Revenue (M USD) and Market Share by Regions 2013-2018
• 7.3 Europe Antidiabetic Thiazolidinediones Price (USD/Unit) by Regions 2013-2018
• 7.4 Europe Antidiabetic Thiazolidinediones Gross Margin by Regions 2013-2018

8 Development Trend for Regions (Sales Point)

• 8.1 Europe Antidiabetic Thiazolidinediones Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.2 Germany Antidiabetic Thiazolidinediones Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.3 UK Antidiabetic Thiazolidinediones Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.4 France Antidiabetic Thiazolidinediones Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.5 Russia Antidiabetic Thiazolidinediones Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.6 Benelux Antidiabetic Thiazolidinediones Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.7 Italy Antidiabetic Thiazolidinediones Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Antidiabetic Thiazolidinediones Sales and Growth, Sales Value and Growth Rate2013-2018
• 8.8 Spain Antidiabetic Thiazolidinediones Sales and Growth, Sales Value and Growth Rate2013-2018

9 Upstream Source, Technology and Cost

• 9.1 Upstream Source
• 9.2 Technology
• 9.3 Cost

10 Channel Analysis

• 10.1 Market Channel
• 10.2 Distributors

11 Consumer Analysis

• 11.1 Hospitals Industry
• 11.2 Clinics Industry
• 11.3 Other Industry

12 Market Forecast 2019-2024

• 12.1 Sales (K Units), Revenue (M USD), Market Share and Growth Rate 2019-2024
  • 12.1.1 Europe Antidiabetic Thiazolidinediones Sales (K Units), Revenue (M USD) and Market Share by Regions 2019-2024
  • 12.1.2 Europe Antidiabetic Thiazolidinediones Sales (K Units) and Growth Rate 2019-2024
  • 12.1.3 Germany Antidiabetic Thiazolidinediones Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.4 UK Antidiabetic Thiazolidinediones Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.5 France Antidiabetic Thiazolidinediones Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.6 Russia Antidiabetic Thiazolidinediones Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.7 Benelux Antidiabetic Thiazolidinediones Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.8 Italy Antidiabetic Thiazolidinediones Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.1.9 Spain Antidiabetic Thiazolidinediones Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.3 Sales (K Units), Revenue (M USD) by Types 2019-2024
  • 12.3.1 Overall Market Performance
  • 12.3.2 Rosiglitazone Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
  • 12.3.3 Pioglitazone Sales (K Units), Revenue (M USD) and Growth Rate 2019-2024
• 12.4 Sales by Application 2019-2024
  • 12.4.1 Overall Market Performance
  • 12.4.2 Hospitals Sales and and Growth Rate 2019-2024
  • 12.4.3 Clinics Sales and and Growth Rate 2019-2024
  • 12.4.4 Other Sales and and Growth Rate 2019-2024
• 12.5 Price (USD/Unit) and Gross Profit
  • 12.5.1 Europe Antidiabetic Thiazolidinediones Price (USD/Unit) Trend 2019-2024
  • 12.5.2 Europe Antidiabetic Thiazolidinediones Gross Profit Trend 2019-2024

13 Conclusion